Hutchmed Reports Positive Phase 3 Trial Results for Non-small Cell Lung Cancer Combination Therapy

MT Newswires · 1d ago
11:55 PM EDT, 08/16/2026 (MT Newswires) -- Hutchmed (China) (HCM.L) reported on Monday positive results from the Saffron phase 3 trial of Orpathys, or savolitinib, plus Tagrisso, or osimertinib, in patients with epidermal growth factor receptor-mutated non-small cell lung cancer. The biopharmaceutical company said the combination formulation achieved "statistically significant and clinically meaningful improvement" in both progression-free survival and overall survival when compared with doublet platinum-based chemotherapy in the trial. The study did not have new safety findings for each component of the formulation. Trial results will be shared with regulators worldwide and presented at an upcoming medical meeting.